TY - JOUR
T1 - Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies
AU - Meyer, Mathias
AU - Vliegenthart, Rozemarijn
AU - Henzler, Thomas
AU - Buergy, Daniel
AU - Giordano, Frank A.
AU - Kostrzewa, Michael
AU - Rathmann, Nils
AU - Brustugun, Odd Terje
AU - Crino, Lucio
AU - Dingemans, Anne-Marie C.
AU - Dusmet, Michael
AU - Fennell, Dean
AU - Grunenwald, Dominique
AU - Huber, Rudolf Maria
AU - Moniuszko, Marcin
AU - Mornex, Francoise
AU - Papotti, Mauro
AU - Pilz, Lothar
AU - Senan, Suresh
AU - Syrigos, Kostas
AU - Perol, Maurice
AU - Gray, Jhanelle E.
AU - Schabel, Christoph
AU - van Meerbeeck, Jan R.
AU - van Zandwijk, Nico
AU - Zhou, Cai Cun
AU - Manegold, Christian
AU - Voigt, Wieland
AU - Roessner, Eric Dominic
PY - 2017/12
Y1 - 2017/12
N2 - Although the effectiveness of screening for lung cancer remains controversial, it is a fact that most lung cancers are diagnosed at an advanced stage outside of lung cancer screening programs. In 2013, the U.S. Preventive Services Task Force revised its lung cancer screening recommendation, now supporting lung cancer screening by low-dose computed tomography in patients at high risk This is also endorsed by many major medical societies and advocacy group stake-holders, albeit with different eligibility criteria. In Europe, population-based lung cancer screening has so far not been recommended or implemented, as some important issues remain unresolved. Among them is the open question of how enlarging pulmonary nodules detected in lung cancer screening should be managed. This article comprises two parts: a review of the current lung cancer screening approaches and the potential therapeutic options for enlarging pulmonary nodules, followed by a meeting report including consensus statements of an interdisciplinary expert panel that discussed the potential of the different therapeutic options. 2017 International Association for the Study of Lung Cancer. (C) Published by Elsevier Inc. All rights reserved.
AB - Although the effectiveness of screening for lung cancer remains controversial, it is a fact that most lung cancers are diagnosed at an advanced stage outside of lung cancer screening programs. In 2013, the U.S. Preventive Services Task Force revised its lung cancer screening recommendation, now supporting lung cancer screening by low-dose computed tomography in patients at high risk This is also endorsed by many major medical societies and advocacy group stake-holders, albeit with different eligibility criteria. In Europe, population-based lung cancer screening has so far not been recommended or implemented, as some important issues remain unresolved. Among them is the open question of how enlarging pulmonary nodules detected in lung cancer screening should be managed. This article comprises two parts: a review of the current lung cancer screening approaches and the potential therapeutic options for enlarging pulmonary nodules, followed by a meeting report including consensus statements of an interdisciplinary expert panel that discussed the potential of the different therapeutic options. 2017 International Association for the Study of Lung Cancer. (C) Published by Elsevier Inc. All rights reserved.
KW - Pulmonary nodules
KW - Lung cancer screening
KW - Surgery
KW - Stereotactic ablative radiotherapy
KW - STEREOTACTIC ABLATIVE RADIOTHERAPY
KW - BODY RADIATION-THERAPY
KW - CLINICAL-PRACTICE GUIDELINES
KW - ED AMERICAN-COLLEGE
KW - SHORT HOOK WIRE
KW - PHASE-II TRIAL
KW - STAGE-I
KW - RADIOFREQUENCY ABLATION
KW - CHEST PHYSICIANS
KW - ESTS GUIDELINES
U2 - 10.1016/j.jtho.2017.09.1956
DO - 10.1016/j.jtho.2017.09.1956
M3 - (Systematic) Review article
C2 - 28962947
SN - 1556-0864
VL - 12
SP - 1755
EP - 1765
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 12
ER -